Advertisement

Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience

  • Filippo SpreaficoEmail author
  • Andrea Ferrari
  • Maurizio Mascarin
  • Paola Collini
  • Carlo Morosi
  • Davide Biasoni
  • Veronica Biassoni
  • Elisabetta Schiavello
  • Lorenza Gandola
  • Giovanna Gattuso
  • Stefano Chiaravalli
  • Maura Massimino
Article
  • 22 Downloads

Abstract

Wilms tumor (or nephroblastoma), rhabdomyosarcoma, and medulloblastoma, common embryonal tumors in children, can occasionally occur in adults, for whom survival is significantly inferior than pediatric patients. Available data on adults with Wilms tumor consist of case or case series reports. Among other factors, the unfamiliarity of adult oncologists and pathologists with nephroblastoma and consequent delays in initiating the appropriate risk-adapted chemotherapy may negatively influence outcomes. The survival decrement in adults with rhabdomyosarcoma has been attributed to the lack of centralized care, the inconsistent use of standard protocol-driven multimodal therapy, and lower chemotherapy tolerance in adult patients. In children with medulloblastoma, evidence from randomized clinical trials has led to risk-tailored therapies tuned on histology, extent of initial disease, and biological features. Such refinements are still missing for adults due to the lack of similar trials and studies that might provide the same or a different understanding regarding patients’ individual prognosis, treatment morbidity, and quality of life. Recent experiences have suggested that applying or adjusting pediatric protocols to adult patients with these tumors is feasible and can improve survival. Here, we provide an evaluation of the current evidence for the management of Wilms tumor, rhabdomyosarcoma, and medulloblastoma arising in adults. This review aims to promote the referral of adolescents and adults with pediatric tumors to pediatric centers for inclusion into pediatric protocols, or into protocols and studies specifically designed for that age group with the cooperation between pediatric and adult oncologists.

Keywords

Wilms tumor Medulloblastoma Rhabdomyosarcoma 

Notes

Acknowledgments

We thank Associazione Bianca Garavaglia Onlus for their constant support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Pastore, G., Znaor, A., Spreafico, F., Graf, N., Pritchard-Jones, K., Steliarova-Foucher, et al. (2006). Malignant renal tumours incidence and survival in European children (1978-1997): report from the automated childhood cancer information system project. European Journal of Cancer, 42(13), 2103–2114.  https://doi.org/10.1016/j.ejca.2006.05.010.CrossRefPubMedGoogle Scholar
  2. 2.
    Spreafico, F., & Bellani, F. F. (2006). Wilms’ tumor: past, present and (possibly) future. Expert Review of Anticancer Therapy, 6(2), 249–258.  https://doi.org/10.1586/14737140.6.2.249.CrossRefPubMedGoogle Scholar
  3. 3.
    Mitry, E., Ciccolallo, L., Coleman, M. P., Gatta, G., & Pritchard-Jones, K. (2006). Incidence of and survival from Wilms’ tumour in adults in Europe: data from the EUROCARE study. European Journal of Cancer, 42(14), 2363–2368.  https://doi.org/10.1016/j.ejca.2006.04.009.CrossRefPubMedGoogle Scholar
  4. 4.
    Izawa, J. I., Al-Omar, M., Winquist, E., Stitt, L., Rodrigues, G., Steele, S., et al. (2008). Prognostic variables in adult Wilms tumour. Canadian Journal of Surgery, 51(4), 252–256.  https://doi.org/10.1016/S0008-428X(08)50070-1.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kattan, J., Tournade, M. F., Culine, S., Terrier-Lacombe, M. J., & Droz, J. P. (1994). Adult Wilms’ tumour: review of 22 cases. European Journal of Cancer, 30(12), 1778–1782.  https://doi.org/10.1016/0959-8049(94)00315-V.CrossRefGoogle Scholar
  6. 6.
    Reinhard, H., Aliani, S., Ruebe, C., Stöckle, M., Leuschner, I., & Graf, N. (2004). Wilms’ tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) study. Journal of Clinical Oncology, 22(22), 4500–4506.  https://doi.org/10.1200/JCO.2004.12.099.CrossRefPubMedGoogle Scholar
  7. 7.
    Terenziani, M., Spreafico, F., Collini, P., Piva, L., Perotti, D., Podda, M., Gandola, L., Massimino, M., Cereda, S., Cefalo, G., Luksch, R., Casanova, M., Ferrari, A., Polastri, D., Valagussa, P., & Fossati-Bellani, F. (2004). Adult Wilms’ tumor: a monoinstitutional experience and a review of the literature. Cancer, 101(2), 289–293.  https://doi.org/10.1002/cncr.20387.CrossRefPubMedGoogle Scholar
  8. 8.
    Treger, T. D., Chowdhury, T., Pritchard-Jones, K., & Behjati, S. (2019). The genetic changes of Wilms tumour. Nature Reviews Nephrology, 15(4), 240–251.  https://doi.org/10.1038/s41581-019-0112-0.CrossRefPubMedGoogle Scholar
  9. 9.
    Rivera, M. N., & Haber, D. A. (2005). Wilms’ tumour: connecting tumorigenesis and organ development in the kidney. Nature Reviews Cancer, 5(9), 699–712.  https://doi.org/10.1038/nrc1696.CrossRefPubMedGoogle Scholar
  10. 10.
    Brok, J., Treger, T. D., Gooskens, S. L., van den Heuvel-Eibrink, M. M., & Pritchard-Jones, K. (2016). Biology and treatment of renal tumours in childhood. European Journal of Cancer, 68, 179–195.  https://doi.org/10.1016/j.ejca.2016.09.005.CrossRefPubMedGoogle Scholar
  11. 11.
    Gadd, S., Huff, V., Walz, A. L., Ooms, A. H. A. G., Armstrong, A. E., Gerhard, D. S., Smith, M. A., Auvil, J. M. G., Meerzaman, D., Chen, Q. R., Hsu, C. H., Yan, C., Nguyen, C., Hu, Y., Hermida, L. C., Davidsen, T., Gesuwan, P., Ma, Y., Zong, Z., Mungall, A. J., Moore, R. A., Marra, M. A., Dome, J. S., Mullighan, C. G., Ma, J., Wheeler, D. A., Hampton, O. A., Ross, N., Gastier-Foster, J. M., Arold, S. T., & Perlman, E. J. (2017). A Children’s Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nature Genetics, 49(10), 1487–1494.  https://doi.org/10.1038/ng.3940.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Scott, R. H., Stiller, C. A., Walker, L., & Rahman, N. (2006). Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. Journal of Medical Genetics, 43(9), 705–715.  https://doi.org/10.1136/jmg.2006.041723.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Trappe, R. U., Riess, H., Lippek, F., Plotkin, M., Schumacher, V., Royer-Pokora, B., et al. (2004). Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms’ tumor and a novel alteration in intron 1 of the WT1 gene. Journal of Pediatric Hematology/Oncology, 26(12), 820–823.PubMedGoogle Scholar
  14. 14.
    Hsiao, H. L., Chang, T. H., Wu, W. J., & Huang, C. H. (2007). Adult Wilms’ tumor with hypospadias and cryptorchidism: a case report. Kaohsiung Journal of Medical Sciences, 23(11), 584–589.PubMedGoogle Scholar
  15. 15.
    Su, M. C., Huang, W. C., & Lien, H. C. (2008). Beta-catenin expression and mutation in adult and pediatric Wilms’ tumors. APMIS, 116(9), 771–778.  https://doi.org/10.1111/j.1600-0463.2008.00914.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Rubin, B. P., Pins, M. R., Nielsen, G. P., Rosen, S., Hsi, B. L., Fletcher, J. A., & Renshaw, A. A. (2000). Isochromosome 7q in adult Wilms’ tumors: diagnostic and pathogenetic implications. American Journal of Surgical Pathology, 24(12), 1663–1669.  https://doi.org/10.1097/00000478-200012000-00011.CrossRefPubMedGoogle Scholar
  17. 17.
    Arrigo, S., Beckwith, J. B., Sharples, K., D’angio, G., & Haase, G. (1990). Better survival after combined modality care for adults with Wilms’ tumor. a report from the national Wilms’ tumor study. Cancer, 66(5), 827–830.  https://doi.org/10.1002/1097-0142(19900901)66:5<827::AID-CNCR2820660502>3.0.CO;2-0.CrossRefPubMedGoogle Scholar
  18. 18.
    Vujanić, G. M., Gessler, M., Ooms, A. H. A. G., Collini, P., Coulomb-l’Hermine, A., D’Hooghe, E., et al. (2018). The UMBRELLA SIOP–RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nature Reviews Urology, 15(11), 693–701.  https://doi.org/10.1038/s41585-018-0100-3.CrossRefPubMedGoogle Scholar
  19. 19.
    Vujanić, G. M., & Sandstedt, B. (2010). The pathology of Wilms’ tumour (nephroblastoma): the International Society of Paediatric Oncology approach. Journal of Clinical Pathology, 63(2), 102–109.  https://doi.org/10.1136/jcp.2009.064600.CrossRefPubMedGoogle Scholar
  20. 20.
    Vujanić, G. M., Sandstedt, B., Kelsey, A., & Sebire, N. J. (2009). Central pathology review in multicenter trials and studies. Cancer, 115(9), 1977–1983.  https://doi.org/10.1002/cncr.24214.CrossRefPubMedGoogle Scholar
  21. 21.
    Oostveen, R. M., & Pritchard-Jones, K. (2019). Pharmacotherapeutic management of Wilms tumor: an update. Pediatric Drugs, 21(1), 1–13.  https://doi.org/10.1007/s40272-018-0323-z.CrossRefPubMedGoogle Scholar
  22. 22.
    Van Den Heuvel-Eibrink, M. M., Hol, J. A., Pritchard-Jones, K., Van Tinteren, H., Furtwängler, R., Verschuur, A. C., et al. (2017). Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nature Reviews Urology, 14(12), 743–752.  https://doi.org/10.1038/nrurol.2017.163.CrossRefPubMedGoogle Scholar
  23. 23.
    Dome, J. S., Graf, N., Geller, J. I., Fernandez, C. V., Mullen, E. A., Spreafico, F., van den Heuvel-Eibrink, M., & Pritchard-Jones, K. (2015). Advances in Wilms tumor treatment and biology: progress through international collaboration. Journal of Clinical Oncology, 33(27), 2999–3007.  https://doi.org/10.1200/JCO.2015.62.1888.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pritchard-Jones, K., Bergeron, C., De Camargo, B., Van Den Heuvel-Eibrink, M. M., Acha, T., Godzinski, J., et al. (2015). Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms’ tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. The Lancet, 386(9999), 1156–1164.  https://doi.org/10.1016/S0140-6736(14)62395-3.CrossRefGoogle Scholar
  25. 25.
    Spreafico, F., Biasoni, D., Lo Vullo, S., Gandola, L., D’Angelo, P., Terenziani, M., et al. (2017). Results of the third AIEOP cooperative protocol on Wilms tumor (TW2003) and related considerations. Journal of Urology, 198(5), 1138–1145.  https://doi.org/10.1016/j.juro.2017.06.081.CrossRefPubMedGoogle Scholar
  26. 26.
    Grundy, P. E., Breslow, N. E., Li, S., Penman, E., Beckwith, J. B., Ritchey, M. L., et al. (2005). Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. Journal of Clinical Oncology, 23(29), 7312–7321.  https://doi.org/10.1200/JCO.2005.01.2799.CrossRefPubMedGoogle Scholar
  27. 27.
    Gratias, E. J., Dome, J. S., Jennings, L. J., Chi, Y. Y., Tian, J., Anderson, J., Grundy, P., Mullen, E. A., Geller, J. I., Fernandez, C. V., & Perlman, E. J. (2016). Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children’s Oncology Group. Journal of Clinical Oncology, 34(26), 3189–3194.  https://doi.org/10.1200/JCO.2015.66.1140.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Byrd, R. L., Evans, A. E., & D’Angio, G. J. (1982). Adult Wilms tumor: effect of combined therapy on survival. Journal of Urology, 127(4), 648–651.  https://doi.org/10.1016/S0022-5347(17)53974-9.CrossRefPubMedGoogle Scholar
  29. 29.
    Kalapurakal, J. A., Nan, B., Norkool, P., Coppes, M., Perlman, E., Beckwith, B., et al. (2004). Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group. International Journal of Radiation Oncology Biology Physics, 60(5), 1379–1384.  https://doi.org/10.1016/j.ijrobp.2004.05.057.CrossRefGoogle Scholar
  30. 30.
    Segers, H., Van Den Heuvel-Eibrink, M. M., & Pritchard-Jones, K. (2011). Management of adults with Wilms’ tumor: recommendations based on international consensus. Expert Review of Anticancer Therapy, 11(7), 1105–1113.  https://doi.org/10.1586/era.11.76.CrossRefPubMedGoogle Scholar
  31. 31.
    Stokes, C. L., Stokes, W. A., Kalapurakal, J. A., Paulino, A. C., Cost, N. G., Cost, C. R., et al. (2018). Timing of radiation therapy in pediatric Wilms tumor: a report from the National Cancer Database. International Journal of Radiation Oncology Biology Physics, 101(2), 453–461.  https://doi.org/10.1016/j.ijrobp.2018.01.110.CrossRefGoogle Scholar
  32. 32.
    Faria, P., Beckwith, J. B., Mishra, K., Zuppan, C., Weeks, D. A., Breslow, N., & Green, D. M. (1996). Focal versus diffuse anaplasia in Wilms tumor-new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. American Journal of Surgical Pathology, 20(8), 909–920.  https://doi.org/10.1097/00000478-199608000-00001.CrossRefPubMedGoogle Scholar
  33. 33.
    Van Den Heuvel-Eibrink, M. M., Graf, N., Pein, F., Sandstedt, B., Van Tinteren, H., Van Der Vaart, K. E., & De Kraker, J. (2004). Intracranial relapse in Wilms tumor patients. Pediatric Blood and Cancer, 43(7), 737–741.  https://doi.org/10.1002/pbc.20150.CrossRefPubMedGoogle Scholar
  34. 34.
    Mir, M. C., Derweesh, I., Porpiglia, F., Zargar, H., Mottrie, A., & Autorino, R. (2017). Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. European Urology, 71(4), 606–617.  https://doi.org/10.1016/j.eururo.2016.08.060.CrossRefPubMedGoogle Scholar
  35. 35.
    Wilde, J. C., Aronson, D. C., Sznajder, B., Van Tinteren, H., Powis, M., Okoye, B., et al. (2014). Nephron sparing surgery (NSS) for unilateral Wilms tumor (UWT): the SIOP 2001 experience. Pediatric Blood & Cancer, 61(12), 2175–2179.  https://doi.org/10.1002/pbc.25185.CrossRefGoogle Scholar
  36. 36.
    Schmidt, A., Warmann, S. W., Urla, C., Schaefer, J., Fideler, F., & Fuchs, J. (2019). Patient selection and technical aspects for laparoscopic nephrectomy in Wilms tumor. Surgical Oncology, 29(November 2018), 14–19.  https://doi.org/10.1016/j.suronc.2019.02.007.CrossRefPubMedGoogle Scholar
  37. 37.
    Lorenzo, A. J., & Romao, R. L. P. (2016). The evolving role of minimally invasive surgery in pediatric and adolescent urologic oncology. Urology, 91, 180–189.  https://doi.org/10.1016/j.urology.2015.12.023.CrossRefPubMedGoogle Scholar
  38. 38.
    Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, et al. (2019). Rhabdomyosarcoma. Nature Reviews Disease Primers, 7;5(1), 1.  https://doi.org/10.1038/s41572-018-0051-2.CrossRefGoogle Scholar
  39. 39.
    Sultan, I., Qaddoumi, I., Yaser, S., Rodriguez-Galindo, C., & Ferrari, A. (2009). Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. Journal of Clinical Oncology, 27(20), 3391–3397.  https://doi.org/10.1200/JCO.2008.19.7483.CrossRefPubMedGoogle Scholar
  40. 40.
    Hawkins, D. S., Chi, Y. Y., Anderson, J. R., Tian, J., Arndt, C. A. S., Bomgaars, L., Donaldson, S. S., Hayes-Jordan, A., Mascarenhas, L., McCarville, M., McCune, J., McCowage, G., Million, L., Morris, C. D., Parham, D. M., Rodeberg, D. A., Rudzinski, E. R., Shnorhavorian, M., Spunt, S. L., Skapek, S. X., Teot, L. A., Wolden, S., Yock, T. I., & Meyer, W. H. (2018). Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the children’s oncology group. Journal of Clinical Oncology, 36(27), 2770–2777.  https://doi.org/10.1200/JCO.2018.77.9694.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bisogno, G., Jenney, M., Bergeron, C., Gallego Melcón, S., Ferrari, A., Oberlin, O., Carli, M., Stevens, M., Kelsey, A., de Paoli, A., Gaze, M. N., Martelli, H., Devalck, C., Merks, J. H., Ben-Arush, M., Glosli, H., Chisholm, J., Orbach, D., Minard-Colin, V., de Salvo, G. L., & European paediatric Soft tissue sarcoma Study Group. (2018). Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. The Lancet Oncology, 19(8), 1061–1071.  https://doi.org/10.1016/S1470-2045(18)30337-1.CrossRefPubMedGoogle Scholar
  42. 42.
    Ferrari, A., Trama, A., De Paoli, A., Bergeron, C., Merks, J. H. M., Jenney, M., et al. (2017). Access to clinical trials for adolescents with soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatric Blood and Cancer, 64(6).  https://doi.org/10.1002/pbc.26348.CrossRefGoogle Scholar
  43. 43.
    Joshi, D., Anderson, J. R., Paidas, C., Breneman, J., Parham, D. M., & Crist, W. (2004). Age is an independent prognostic factor in rhabdomyosarcoma: a report from the soft tissue sarcoma Committee of the Children’s Oncology Group. Pediatric Blood and Cancer, 42(1), 64–73.  https://doi.org/10.1002/pbc.10441.CrossRefPubMedGoogle Scholar
  44. 44.
    Bisogno, G., Compostella, A., Ferrari, A., Pastore, G., Cecchetto, G., Garaventa, A., Indolfi, P., de Sio, L., & Carli, M. (2012). Rhabdomyosarcoma in adolescents: a report from the AIEOP Soft Tissue Sarcoma Committee. Cancer, 118(3), 821–827.  https://doi.org/10.1002/cncr.26355.CrossRefPubMedGoogle Scholar
  45. 45.
    Trama, A., Botta, L., Foschi, R., Ferrari, A., Stiller, C., Desandes, E., Maule, M. M., Merletti, F., Gatta, G., & EUROCARE-5 Working Group. (2016). Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. The Lancet Oncology, 17(7), 896–906.  https://doi.org/10.1016/S1470-2045(16)00162-5.CrossRefPubMedGoogle Scholar
  46. 46.
    Van Gaal, J. C., Van Der Graaf, W. T. A., Rikhof, B., Van Hoesel, Q. G. C. M., Teerenstra, S., Suurmeijer, A. J. H., et al. (2012). The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Research, 32(10), 4485–4498.PubMedGoogle Scholar
  47. 47.
    Esnaola, N. F., Rubin, B. P., Baldini, E. H., Vasudevan, N., Demetri, G. D., Fletcher, C. D. M., & Singer, S. (2001). Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Annals of Surgery, 234(2), 215–223.  https://doi.org/10.1097/00000658-200108000-00012.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Hawkins, W. G., Hoos, A., Antonescu, C. R., Urist, M. J., Leung, D. H. Y., Gold, J. S., et al. (2001). Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer, 91(4), 794–803.  https://doi.org/10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q.CrossRefPubMedGoogle Scholar
  49. 49.
    Little, D. J., Ballo, M. T., Zagars, G. K., Pisters, P. W. T., Patel, S. R., El-Naggar, A. K., et al. (2002). Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer, 95(2), 377–388.  https://doi.org/10.1002/cncr.10669.CrossRefPubMedGoogle Scholar
  50. 50.
    Ferrari, A., Dileo, P., Casanova, M., Bertulli, R., Meazza, C., Gandola, L., et al. (2003). Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. Cancer, 98(3), 571–580.  https://doi.org/10.1002/cncr.11550.CrossRefPubMedGoogle Scholar
  51. 51.
    Dumont, S. N., Araujo, D. M., Munsell, M. F., Salganick, J. A., Dumont, A. G., Raymond, K. A., Linassier, C., Patel, S., Benjamin, R. S., & Trent, J. C. (2013). Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Medicine, 2(4), 553–563.  https://doi.org/10.1002/cam4.92.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gerber, N. K., Wexler, L. H., Singer, S., Alektiar, K. M., Keohan, M. L., Shi, W., Zhang, Z., & Wolden, S. (2013). Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. International Journal of Radiation Oncology Biology Physics, 86(1), 58–63.  https://doi.org/10.1016/j.ijrobp.2012.12.016.CrossRefGoogle Scholar
  53. 53.
    Fischer, T. D., Gaitonde, S. G., Bandera, B. C., Raval, M. V., Vasudevan, S. A., Gow, K. W., et al. (2018). Pediatric-protocol of multimodal therapy is associated with improved survival in AYAs and adults with rhabdomyosarcoma. Surgery (United States), 163(2), 324–329.  https://doi.org/10.1016/j.surg.2017.10.027.CrossRefGoogle Scholar
  54. 54.
    Bergamaschi, L., Bertulli, R., Casanova, M., Provenzano, S., Chiaravalli, S., Gasparini, P., Collini, P., Sangalli, C., Gandola, L., Diletto, B., Morosi, C., Fiore, M., Massimino, M., & Ferrari, A. (2019). Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. Medical Oncology, 36(7), 1–8.  https://doi.org/10.1007/s12032-019-1282-0.CrossRefGoogle Scholar
  55. 55.
    Gaffney, E. F., Dervan, P. A., & Fletcher, C. D. (1993). Pleomorphic rhabdomyosarcoma in adulthood. Analysis of 11 cases with definition of diagnostic criteria. The American Journal of Surgical Pathology, 17(6), 601–609.CrossRefGoogle Scholar
  56. 56.
    van der Graaf, W. T. A., Orbach, D., Judson, I. R., & Ferrari, A. (2017). Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. The Lancet Oncology, 18(3), e166–e175.  https://doi.org/10.1016/S1470-2045(17)30099-2.CrossRefPubMedGoogle Scholar
  57. 57.
    Ferrari, A., Bleyer, A., Patel, S., Chiaravalli, S., Gasparini, P., & Casanova, M. (2018). The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatric Blood and Cancer, 65(7), 1–8.  https://doi.org/10.1002/pbc.27013.CrossRefGoogle Scholar
  58. 58.
    Ferrari, A., Miceli, R., Casanova, M., Meazza, C., Favini, F., Luksch, R., Catania, S., Fiore, M., Morosi, C., & Mariani, L. (2010). The symptom interval in children and adolescents with soft tissue sarcomas. Cancer, 116(1), 177–183.  https://doi.org/10.1002/cncr.24695.CrossRefPubMedGoogle Scholar
  59. 59.
    Davis, L. E., Janeway, K. A., Weiss, A. R., Chen, Y. L. E., Scharschmidt, T. J., Krailo, M., et al. (2017). Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer, 123(18), 3434–3440.  https://doi.org/10.1002/cncr.30757.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Altaf, S., Enders, F., Lyden, E., Donaldson, S. S., Rodeberg, D., & Arndt, C. (2014). Age-related toxicity in patients with rhabdomyosarcoma: a report from the children’s oncology group. Journal of Pediatric Hematology/Oncology, 36(8), 599–604.  https://doi.org/10.1097/MPH.0000000000000192.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Gupta, A. A., Anderson, J. R., Pappo, A. S., Spunt, S. L., Dasgupta, R., Indelicato, D. J., & Hawkins, D. S. (2012). Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer, 118(4), 1130–1137.  https://doi.org/10.1002/cncr.26358.CrossRefPubMedGoogle Scholar
  62. 62.
    Gasparini, P., Fortunato, O., De Cecco, L., Casanova, M., Iannó, M. F., Carenzo, A., et al. (2019). Age-related alterations in immune contexture are associated with aggressiveness in rhabdomyosarcoma. Cancers, 11(9), 1380.  https://doi.org/10.3390/cancers11091380.CrossRefPubMedCentralGoogle Scholar
  63. 63.
    Merchant, T. E., Pollack, I. F., & Loeffler, J. S. (2010). Brain tumors across the age spectrum: biology, therapy, and late effects. Seminars in Radiation Oncology, 20(1), 58–66.  https://doi.org/10.1016/j.semradonc.2009.09.005.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Massimino, M., Biassoni, V., Gandola, L., Garrè, M. L., Gatta, G., Giangaspero, F., et al. (2016, September 1). Childhood medulloblastoma. In Critical Reviews in Oncology/Hematology, 105:35–51. Elsevier Ireland: Ltd.  https://doi.org/10.1016/j.critrevonc.2016.05.012.CrossRefGoogle Scholar
  65. 65.
    Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., et al. (2019). Medulloblastoma. Nature Reviews Disease Primers, 14;5(1), 11.  https://doi.org/10.1038/s41572-019-0063-6.CrossRefGoogle Scholar
  66. 66.
    Juraschka, K., & Taylor, M. D. (2019). Medulloblastoma in the age of molecular subgroups: a review. Journal of Neurosurgery: Pediatrics, 24(4), 353–363.  https://doi.org/10.3171/2019.5.peds18381.CrossRefPubMedGoogle Scholar
  67. 67.
    Majd, N., & Penas-Prado, M. (2019). Updates on management of adult medulloblastoma. Current Treatment Options in Oncology, 20(8), 64–24.  https://doi.org/10.1007/s11864-019-0663-0.CrossRefPubMedGoogle Scholar
  68. 68.
    Atalar, B., Ozsahin, M., Call, J., Napieralska, A., Kamer, S., Villa, S., Erpolat, P., Negretti, L., Lassen-Ramshad, Y., Onal, C., Akyurek, S., Ugurluer, G., Baumert, B. G., Servagi-Vernat, S., Miller, R. C., Ozyar, E., & Sio, T. T. (2018). Treatment outcome and prognostic factors for adult patients with medulloblastoma: the Rare Cancer Network (RCN) experience. Radiotherapy and Oncology, 127(1), 96–102.  https://doi.org/10.1016/j.radonc.2017.12.028.CrossRefPubMedGoogle Scholar
  69. 69.
    Kann, B. H., Lester-Coll, N. H., Park, H. S., Yeboa, D. N., Kelly, J. R., Baehring, J. M., Becker, K. P., Yu, J. B., Bindra, R. S., & Roberts, K. B. (2017). Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology, 19(2), 259–269.  https://doi.org/10.1093/neuonc/now150.CrossRefPubMedGoogle Scholar
  70. 70.
    Chang, C. H., Housepian, E. M., & Herbert, C. (1969). An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology, 93(6), 1351–1359.  https://doi.org/10.1148/93.6.1351.CrossRefPubMedGoogle Scholar
  71. 71.
    Michalski, J. M., Janss, A., Vezina, G., Gajjar, A., Pollack, I., Merchant, T. E., et al. (2016). Results of COG ACNS0331: a phase III trial of involved-field radiotherapy (IFRT) and low-dose craniospinal irradiation (LD-CSI) with chemotherapy in average-risk medulloblastoma: a report from the Children’s Oncology Group, ASTRO meeting 2016. International Journal of Radiation Oncology Biology Physics, 5, 937–938.CrossRefGoogle Scholar
  72. 72.
    Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., et al. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31(6), 737–754.e6.  https://doi.org/10.1016/j.ccell.2017.05.005.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Remke, M., Hielscher, T., Northcott, P. A., Witt, H., Ryzhova, M., Wittmann, A., Benner, A., von Deimling, A., Scheurlen, W., Perry, A., Croul, S., Kulozik, A. E., Lichter, P., Taylor, M. D., Pfister, S. M., & Korshunov, A. (2011). Adult medulloblastoma comprises three major molecular variants. Journal of Clinical Oncology, 29(19), 2717–2723.  https://doi.org/10.1200/JCO.2011.34.9373.CrossRefPubMedGoogle Scholar
  74. 74.
    Brandes, A. A., Bartolotti, M., Marucci, G., Ghimenton, C., Agati, R., Fioravanti, A., Mascarin, M., Volpin, L., Ammannati, F., Masotto, B., Gardiman, M. P., de Biase, D., Tallini, G., Crisi, G., Bartolini, S., & Franceschi, E. (2015). New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Critical Reviews in Oncology/Hematology, 94(3), 348–359.  https://doi.org/10.1016/j.critrevonc.2014.12.016.CrossRefPubMedGoogle Scholar
  75. 75.
    Frappaz, D., Faure-Conter, C., Bonneville Levard, A., Barritault, M., Meyronet, D., & Sunyach, M. P. (2018). Medulloblastomas in adolescents and adults–can the pediatric experience be extrapolated? Neurochirurgie.  https://doi.org/10.1016/j.neuchi.2018.10.007.
  76. 76.
    Carrie, C., Lasset, C., Alapetite, C., Maire, J. -P., Haie-Meder, C., Hoffstetter, S., et al. (1994). Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer, 74(8), 2352–2360.  https://doi.org/10.1002/1097-0142(19941015)74:8<2352::AID-CNCR2820740821>3.0.CO;2-H.CrossRefGoogle Scholar
  77. 77.
    Brandes, A. A., Franceschi, E., Tosoni, A., Frezza, G., Agati, R., Maestri, A., et al. (2010). Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: a large prospective phase II trial. Journal of Clinical Oncology, 28(15_suppl), 2003–2003.  https://doi.org/10.1200/jco.2010.28.15_suppl.2003.CrossRefGoogle Scholar
  78. 78.
    Kocakaya, S., Beier, C. P., & Beier, D. (2016). Chemotherapy increases long-term survival in patients with adult medulloblastoma-a literature-based meta-analysis. Neuro-Oncology, 18(3), 408–416.  https://doi.org/10.1093/neuonc/nov185.CrossRefPubMedGoogle Scholar
  79. 79.
    Brandes, A. A., Ermani, M., Amista, P., Basso, U., Vastola, F., Gardiman, M., et al. (2003). The treatment of adults with medulloblastoma: a prospective study. International Journal of Radiation Oncology Biology Physics, 57(3), 755–761.  https://doi.org/10.1016/S0360-3016(03)00643-6.CrossRefGoogle Scholar
  80. 80.
    Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., & Ermani, M. (2007). Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer, 110(9), 2035–2041.  https://doi.org/10.1002/cncr.23003.CrossRefPubMedGoogle Scholar
  81. 81.
    Beier, D., Proescholdt, M., Reinert, C., Pietsch, T., Jones, D. T. W., Pfister, S. M., Hattingen, E., Seidel, C., Dirven, L., Luerding, R., Reijneveld, J., Warmuth-Metz, M., Bonsanto, M., Bremer, M., Combs, S. E., Rieken, S., Herrlinger, U., Kuntze, H., Mayer-Steinacker, R., Moskopp, D., Schneider, T., Beringer, A., Schlegel, U., Stummer, W., Welker, H., Weyerbrock, A., Paulsen, F., Rutkowski, S., Weller, M., Wick, W., Kortmann, R. D., Bogdahn, U., & Hau, P. (2018). Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 20(3), 400–410.  https://doi.org/10.1093/neuonc/nox155.CrossRefPubMedGoogle Scholar
  82. 82.
    Friedrich, C., Von Bueren, A. O., Von Hoff, K., Kwiecien, R., Pietsch, T., Warmuth-Metz, M., et al. (2013). Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. European Journal of Cancer, 49(4), 893–903.  https://doi.org/10.1016/j.ejca.2012.10.006.CrossRefPubMedGoogle Scholar
  83. 83.
    Franceschi, E., Bartolotti, M., Paccapelo, A., Marucci, G., Agati, R., Volpin, L., Danieli, D., Ghimenton, C., Gardiman, M. P., Sturiale, C., Poggi, R., Mascarin, M., Balestrini, D., Masotto, B., & Brandes, A. A. (2016). Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? Journal of Neuro-Oncology, 128(2), 235–240.  https://doi.org/10.1007/s11060-016-2097-x.CrossRefPubMedGoogle Scholar
  84. 84.
    Padovani, L., Sunyach, M. P., Perol, D., Mercier, C., Alapetite, C., Haie-Meder, C., et al. (2007). Common strategy for adult and pediatric medulloblastoma:a multicenter series of 253 adults. International Journal of Radiation Oncology Biology Physics, 68(2), 433–440.  https://doi.org/10.1016/j.ijrobp.2006.12.030.CrossRefGoogle Scholar
  85. 85.
    De, B., Beal, K., De Braganca, K. C., Souweidane, M. M., Dunkel, I. J., Khakoo, Y., et al. (2018). Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. Journal of Neuro-Oncology, 136(1), 95–104.  https://doi.org/10.1007/s11060-017-2627-1.CrossRefPubMedGoogle Scholar
  86. 86.
    Harrison, R. A., Kesler, S. R., Johnson, J. M., Penas-Prado, M., Sullaway, C. M., & Wefel, J. S. (2019). Neurocognitive dysfunction in adult cerebellar medulloblastoma. Psycho-Oncology, 28(1), 131–138.  https://doi.org/10.1002/pon.4920.CrossRefPubMedGoogle Scholar
  87. 87.
    Von Bueren, A. O., Friedrich, C., Von Hoff, K., Kwiecien, R., Müller, K., Pietsch, T., et al. (2015). Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol. European Journal of Cancer, 51(16), 2434–2443.  https://doi.org/10.1016/j.ejca.2015.06.124.CrossRefGoogle Scholar
  88. 88.
    Spreafico, F., Massimino, M., Gandola, L., Cefalo, G., Mazza, E., Landonio, G., Pignoli, E., Poggi, G., Terenziani, M., Pedrazzoli, P., Siena, S., & Fossati-Bellani, F. (2005). Survival of adults treated for medulloblastoma using paediatric protocols. European Journal of Cancer, 41(9), 1304–1310.  https://doi.org/10.1016/j.ejca.2005.02.022.CrossRefPubMedGoogle Scholar
  89. 89.
    Chen, I., Pasalic, D., Fischer-Valuck, B., Frangoul, H., DeWees, T., Shinohara, E. T., & Perkins, S. M. (2018). Disparity in outcomes for adolescent and young adult patients diagnosed with pediatric solid tumors across 4 decades. American Journal of Clinical Oncology: Cancer Clinical Trials, 41(5), 471–475.  https://doi.org/10.1097/COC.0000000000000304.CrossRefGoogle Scholar
  90. 90.
    Bleyer, A., Budd, T., & Montello, M. (2006). Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer, 107(7 SUPPL), 1645–1655.  https://doi.org/10.1002/cncr.22102.CrossRefPubMedGoogle Scholar
  91. 91.
    Peppercorn, J. M., Weeks, J. C., Cook, E. F., & Joffe, S. (2004). Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet, 363(9405), 263–270.  https://doi.org/10.1016/S0140-6736(03)15383-4.CrossRefPubMedGoogle Scholar
  92. 92.
    Mascarin, M., Coassin, E., Franceschi, E., Gandola, L., Carrabba, G., Brandes, A. A., & Massimino, M. (2019). Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable? Child’s Nervous System., 35, 2279–2287.  https://doi.org/10.1007/s00381-019-04340-8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Filippo Spreafico
    • 1
    Email author
  • Andrea Ferrari
    • 1
  • Maurizio Mascarin
    • 2
  • Paola Collini
    • 3
  • Carlo Morosi
    • 4
  • Davide Biasoni
    • 5
  • Veronica Biassoni
    • 1
  • Elisabetta Schiavello
    • 1
  • Lorenza Gandola
    • 6
  • Giovanna Gattuso
    • 1
  • Stefano Chiaravalli
    • 1
  • Maura Massimino
    • 1
  1. 1.Department of Medical Oncology and Hematology, Pediatric Oncology UnitFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  2. 2.SOSD Oncologia Integrata del Giovane e Radioterapia PediatricaCentro di Riferimento Oncologico (CRO) IRCCSAvianoItaly
  3. 3.Department of Diagnostic Pathology and Laboratory MedicineFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  4. 4.Department of RadiologyFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  5. 5.Testis Surgery UnitFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  6. 6.Pediatric Radiotherapy Unit, Radiation Oncology 1 Unit, Department of Radiation OncologyFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly

Personalised recommendations